A Post-market Registry of Patients With de Novo Lesions in Previously Untreated Vessels Treated With Absorb BVS
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms ABSORB UK
- Sponsors Abbott Vascular
- 09 Jan 2018 Planned End Date changed from 1 Sep 2018 to 1 Nov 2018.
- 09 Jan 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Nov 2018.
- 10 Jun 2017 Biomarkers information updated